Citadel Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Citadel Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-16,500	Closed	-$63K	–	10134
2019 Q3	$63K	Buy	16,500 +4,600	+39%	+$16.6K	﹤0.01%	8648
2019 Q2	$79K	Buy	+11,900	New	+$45.3K	﹤0.01%	8605
2019 Q1	–	Sell	-2,520	Closed	-$10K	–	10198
2018 Q4	$10K	Sell	2,520 -1,580	-39%	-$20.2K	﹤0.01%	8931
2018 Q3	$81K	Sell	4,100 -2,800	-41%	-$70.8K	﹤0.01%	8658
2018 Q2	$219K	Buy	6,900 +4,540	+192%	+$163K	﹤0.01%	7743
2018 Q1	$87K	Buy	+2,360	New	+$155K	﹤0.01%	7762

Citadel Advisors's MLNT Position: Q1 2020 in Review

Citadel Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 56,839 shares — an estimated $30K sold.

Citadel Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $469K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Citadel Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Citadel Advisors sold 56,839 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $30K.
Citadel Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Citadel Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $469K in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.